Cancer feature: cnaPANCAN356

AC013269.5 AC114783.1 AC140481.2 ACMSD AMER3 AMMECR1L ANKRD30BL ARHGAP15 ARHGEF4 BIN1 C2orf27A C2orf27B CCDC115 CCDC74A CCDC74B CCNT2 CFC1 CFC1B CLASP1 CNTNAP5 CXCR4 CYP27C1 DARS ERCC3 FAM168B GLI2 GPR148 GPR17 GPR39 GTDC1 GYPC HNMT HS6ST1 IMP4 IWS1 KYNU LCT LIMS2 LRP1B LYPD1 MAP3K19 MAP3K2 MCM6 MGAT5 MYO7B MZT2A MZT2B NCKAP5 NIFK NXPH2 PLEKHB2 POLR2D POTEF POTEI POTEJ PROC PTPN18 R3HDM1 RAB3GAP1 RAB6C SAP130 SFT2D3 SMPD4 SPOPL TFCP2L1 THSD7B TMEM163 TSN TUBA3D TUBA3E UBXN4 UGGT1 WDR33 ZEB2 ZRANB3

Known Driver Genes: ERCC3

Copy number alternation: loss

MK-1775

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer